
Pharmacology
Latest News
Latest Videos

Shorts










More News

Among children treated with navepegritide throughout the double-blind period, mean TFA decreased from 9.1° at baseline to 7.7° at Week 52 and 6.9° at Week 104, a mean absolute change of −2.2° over 2 years.

Newborn screening speeds SMA treatment, and a first prenatal risdiplam case hints at preventing motor neuron loss before birth.

Two-year data from the pivotal ApproaCH trial showed sustained growth improvements with TransCon CNP in pediatric achondroplasia.

Learn how to spot and treat pediatric insomnia: sleep hygiene first, behavioral tools, and when melatonin or other off-label meds fit.

FDA green-lights Imcivree for acquired hypothalamic obesity in patients 4 years and older, delivering major reductions in BMI and hunger in phase 3.

New international pediatric HAE guideline recommends oral sebetralstat as first-line acute therapy for adolescents 12 years and older.

FDA clears first at-home test to detect RSV, influenza, and COVID-19 in infants as young as 6 months
FDA-cleared Flowflex Plus 4-in-1 home test detects RSV, influenza A/B, and COVID-19 in adults and children as young as 6 months.

A large 2026 meta-analysis found no association between prenatal paracetamol (acetaminophen) use and autism, ADHD, or intellectual disability in children.

This recent FDA clearance expands the use of the iotaSOFT Insertion System for pediatric use.

Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia
Findings from a phase 2 trial showed that once-weekly TransCon CNP plus TransCon hGH produced durable growth and proportionality benefits in children with achondroplasia.

The FDA approved narsoplimab-wuug as the first targeted treatment for transplant-associated thrombotic microangiopathy in adults and children.

Take a look back at the top 5 FDA approvals of 2025.

Check out the top 5 pharmacology articles of 2025.

Approval of the expanded indication fullfilled all post-marketing requirements outlined in the original approval letter.

Ferric maltol is now an FDA-approved oral iron therapy for both adults and adolescents with iron deficiency, aged 10 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Once-weekly navepegritide improved growth velocity, skeletal alignment, and functional outcomes in children with achondroplasia, with a favorable safety profile and potential implications for long-term care.

The FDA approved fibrinogen, human-chmt to treat acute bleeding episodes in adult and pediatric patients with congenital fibrinogen deficiency.

Abbott received FDA clearance for a new delivery system designed to simplify PDA closure in premature infants weighing as little as 2 lb.














